Cantor Fitzgerald has reiterated its 'Overweight' rating on Core Scientific but reduced its price target from $39 to $30. This adjustment indicates a revised valuation outlook for the company, suggesting a more cautious but still positive stance from the analyst.
Cantor Fitzgerald analyst Brett Knoblauch maintained an 'Overweight' rating on Core Scientific (CORZ) but lowered the price target from $39 to $30. This action signals a more conservative valuation for the company, likely due to updated financial models, market conditions, or industry outlooks. While the 'Overweight' rating suggests continued confidence in the stock's potential to outperform, the reduced price target could lead to short-term negative sentiment and selling pressure as investors adjust their expectations. For traders, this presents a potential opportunity to re-evaluate CORZ's current valuation against the new target, with the long-term outlook still positive according to Cantor Fitzgerald, but with a reduced upside.